Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Roche : Aspen welcomes decision to drop price probe

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 03:56pm CEST

JOHANNESBURG - Aspen yesterday welcomed the Competition Commission's decision to drop the excessive pricing investigations against it and agent Equity.

The commission yesterday halted its probe, charging that it could not sustain a case of excessive pricing against it.

However, it said its investigations into Roche, US-based technology company Genentech and Pfizer were continuing. Aspen chief executive Stephen Saad said the decision to investigate was expeditious and co-operative.

The decision follows the commission’s initiation of investigations against Aspen, Roche, Genentech, Pfizer and Equity in June for suspected abuse of dominance and excessive pricing in the provision of specific cancer medicines in South Africa. When the commission announced the probe, Commissioner Tembinkosi Bonakele said the anti-graft agency had identified the health-care sector, and in particular pharmaceuticals, as a priority sector for its enforcement efforts “due to the likely negative impact that anti-competitive conduct in that sector would have on consumers in general and specifically the poor and vulnerable”.

Yesterday, the commission said the Aspen probe revealed that the revenue attributable to Myleran, Alkeran and Leukeran was low as the products were at the end of their lifespans. “In respect of Equity, the investigation revealed that the drug, Xalkori Crizotinib, is not yet registered in South Africa. It was imported once with the permission of the Medicines Control Council. The high price charged by Equity was as a result of high cost incurred in importing the product from Germany,” the commission said.

“It is, therefore, unlikely that the price charged by Equity could pass the test for excessive pricing.” The commission, however, alleged that Roche and Genentech had engaged in excessive pricing, price discrimination and exclusionary conduct in the provision of breast cancer medicine in South Africa, adding that breast cancer treatment was unaffordable in South Africa.

The commission said investigations on Pfizer for excessive pricing of lung cancer medication in South Africa would continue. The drug maker was the only provider of a lung cancer treatment medication, known asXalkori (crizotinib), in South Africa. The body also alleged that lung cancer treatment in South Africa was unaffordable.

Aspen shares fell 0.01 percent on the JSE yesterday to close at R304.75 a share.


(c) Cape Community 1999 - 2017 Independent Newspapers (Pty) Limited. All rights strictly reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER -0.80% 37.36 Delayed Quote.3.98%
ROCHE HOLDING LTD. 0.22% 232.4 Delayed Quote.-5.90%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
07:01aGENENTECH : to Present New Data Demonstrating the Breadth and Depth of Its Alzhe..
07/19Finance Chiefs Say Too Much Data Is Making It Harder to Keep on Top of Risks
07/19GENENTECH : ’s TECENTRIQ in Combination With Pemetrexed and Platinum-Based..
07/18ROCHE : FDA Grants Breakthrough Therapy Designation for Genentech’s TECENT..
07/17ROCHE : Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Sympto..
07/12GENENTECH : Announces Submission of Supplemental New Drug Application for Vencle..
07/09Trump slams Pfizer after July 1 drug price hikes
07/06HITTING CANCER EARLY : AstraZeneca's bid to outmaneuver rivals
07/06Hitting cancer early - AstraZeneca's bid to outmanoeuvre rivals
07/02ROCHE : Phase III IMpassion130 Study Showed Genentech’s TECENTRIQ Plus Abr..
More news
News from SeekingAlpha
02:36aAllergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To .. 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/19Allergan's abicipar on par with Lucentis in two late-stage AMD studies; share.. 
07/19Roche's Tecentriq shows treatment benefit in late-stage lung cancer study 
07/19YOUR DAILY PHARMA SCOOP : Voyager Advances, Roche Succeeds, Eisai Positive 
Financials (CHF)
Sales 2018 55 561 M
EBIT 2018 18 595 M
Net income 2018 11 884 M
Debt 2018 4 021 M
Yield 2018 3,71%
P/E ratio 2018 16,27
P/E ratio 2019 15,85
EV / Sales 2018 3,73x
EV / Sales 2019 3,58x
Capitalization 203 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 256  CHF
Spread / Average Target 10%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-5.90%203 399
JOHNSON & JOHNSON-8.53%346 292
PFIZER3.98%220 236
NOVARTIS-1.75%200 139
MERCK AND COMPANY11.09%168 225
AMGEN10.27%128 318